Press Releases

You Narrowed By: Business/Product Release

Showing 36-70 of 174

First Prev 1 2 3 4 5 Next Last

2012
September
September 12	According to New Survey, Most Men are Not Proactive about Their Health Despite the Desire to Live Long Lives
September 6	Abbott to Collaborate with Astellas in CMV Vaccine Trial

August
August 30	Abbott's HUMIRA® (Adalimumab) Approved in Europe for Expanded Treatment of Crohn’s Disease (CD)
August 28	Abbott Announces CE Mark for Highly Sensitive Testosterone Test to Measure the Hormone at Low Levels
August 20	Abbott Announces CE Mark and European Launch of Next-Generation XIENCE Xpedition™ Drug Eluting Stent
August 7	Abbott's Omnilink Elite® Vascular Balloon-Expandable Stent System Receives FDA Approval for Treatment of Iliac Artery Disease

July
July 30	Abbott's HUMIRA® (adalimumab) Approved in Europe for Treatment of Non-radiographic Axial Spondyloarthritis (nr-axSpA)
July 13	Abbott Focuses on the Importance of Information Management and Automation at the American Association for Clinical Chemistry Lab Expo
July 11	Abbott Introduces OneLab, a Novel Integrated Web-Based Software Platform to Manage the Vast Amounts of Information Flowing Through the Lab
July 10	Abbott Announces New Test for the Management of Patients with Diabetes
July 3	Abbott Receives FDA Approval for Healon EndoCoat Protective Gel for Cataract Surgery

June
June 26	Abbott Introduces New Limited Ingredient Nutrition Bar – Perfectly Simple™ by ZonePerfect®
June 25	Abbott Receives Positive Opinion for HUMIRA® in Non-radiographic Axial Spondyloarthritis from EMA's CHMP
June 18	Abbott Presents Results of Clinical Studies Evaluating Its Investigational Treatment for Advanced Parkinson's Disease
June 12	Abbott Expands CFChef Program in 2012 for People Affected by Cystic Fibrosis
June 6	Abbott Presents Phase 3 Study Results for Investigational Use of HUMIRA® (Adalimumab) in Patients with Active Non-radiographic Axial Spondyloarthritis
June 6	Abbott Presents Phase 3 Study Results for Investigational Use of HUMIRA® (Adalimumab) in Patients with Active Peripheral Spondyloarthritis
June 6	Abbott Announces 10-Year Data Evaluating HUMIRA® (Adalimumab) for Patients with Long-Standing Moderate-to-Severe Rheumatoid Arthritis
June 5	Abbott Introduces Ensure Clear™ to Help Adults Fill Dietary Gap
June 5	Abbott Announces Initiation of Phase 3 Study of Elagolix in Patients with Endometriosis

May
May 29	Abbott to Present Wide Range of Investigational Efficacy, Safety and Health Outcomes Data on HUMIRA® (Adalimumab) at the Annual Meeting of the European League Against Rheumatism - (Europe)
May 29	Abbott to Present Wide Range of Investigational Efficacy, Safety and Health Outcomes Data on HUMIRA® (Adalimumab) at the Annual Meeting of the European League Against Rheumatism - (U.S.)
May 16	Abbott Launches PediaSure SideKicks® Clear for Picky Eaters
May 15	Abbott's XIENCE PRIME™ and XIENCE V® Drug Eluting Stents Receive Indication in Europe for Minimum Three-Month Duration of Dual Anti-Platelet Therapy
May 7	Abbott Reaches Settlement Agreement on Depakote
May 3	Abbott Announces Collaboration with Syngene to Open First Nutrition R&D Center in India
May 3	Abbott to Acquire Action Pharma's Investigational Compound, AP214, in Phase 2b Development for Prevention of Acute Kidney Injury

April
April 25	New Products from Abbott’s EAS® Sports Nutrition Brand Help Athletes Improve Post-Workout Recovery and Meet Fitness Goals
April 23	Abbott and St. Jude Medical Broaden Alliance for Cardiovascular Products in the United States
April 20	Abbott Receives U.S. FDA Clearance to Use iFS Advanced Femtosecond Laser Technology for Arcuate Incisions in Cataract Surgery
April 19	Abbott Presents Positive Results from Phase 2 "Pilot" Study of an Interferon-Free Combination Regimen for the Treatment of Hepatitis C
April 19	Abbott Presents Positive Results from Interferon-Free Phase 2 "Co-Pilot" Study for the Treatment of Hepatitis C
April 17	Abbott Licenses Biomarkers for Use in Differentiating Aggressive from Nonaggressive Prostate Cancer
April 17	Abbott’s Investigational Treatment for Advanced Parkinson’s Disease Demonstrates Positive Results in Phase 3 Clinical Trial
April 11	Abbott's HUMIRA® (adalimumab) Approved in Europe for Treatment of Ulcerative Colitis (UC)

First Prev 1 2 3 4 5 Next Last

Narrow by Year

Narrow to Show

For a different perspective on Abbott News. . .

View Abbott Feature Stories

© 2006, 2013 Abbott Laboratories, Abbott Park, Illinois, USA

Unless otherwise specified, all product names appearing in this Internet site are trademarks owned by or licensed to Abbott Laboratories, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott Laboratories, except to identify the product or services of the company.